Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study
Open Access
- 19 September 2017
- journal article
- research article
- Published by Hindawi Limited in Stem Cells International
- Vol. 2017, 1-8
- https://doi.org/10.1155/2017/8506370
Abstract
Background. Ischemic heart failure (IHF) has a poor prognosis in spite of optimal therapy. We have established a new allogeneic Cardiology Stem Cell Centre adipose-derived stromal cell (CSCC_ASC) product from healthy donors. It is produced without animal products, in closed bioreactor systems and cryopreserved as an off-the-shelf product ready to use. Study Design. A multicentre, double-blind, placebo-controlled phase II study with direct intramyocardial injections of allogeneic CSCC_ASC in patients with chronic IHF. A total of 81 patients will be randomised at 2 : 1 to CSCC_ASC or placebo. There is no HLA tissue type matching needed between the patients and the donors. Methods. The treatment will be delivered by direct injections into the myocardium. The primary endpoint is change in the left ventricle endsystolic volume at 6-month follow-up. Secondary endpoints are safety and changes in left ventricle ejection fraction, myocardial mass, stroke volume, and cardiac output. Other secondary endpoints are change in clinical symptoms, 6-minute walking test, and the quality of life after 6 and 12 months. Conclusion. The aim of the present study is to demonstrate safety and the regenerative efficacy of the allogeneic CSCC_ASC product from healthy donors in a double-blind, placebo-controlled, multicentre study in patients with IHF.Keywords
Funding Information
- Arvid Nilsson Foundation (6153-00002A)
This publication has 35 references indexed in Scilit:
- Mesenchymal stromal cell therapy in ischemic heart diseaseScandinavian Cardiovascular Journal, 2016
- Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissueScandinavian Journal of Clinical and Laboratory Investigation, 2016
- Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)European Heart Journal, 2015
- Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in Patients With Acute Myocardial Infarction Based on Individual Patient DataCirculation Research, 2015
- The Global Health and Economic Burden of Hospitalizations for Heart FailureJournal of the American College of Cardiology, 2014
- Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina — Final 3-year follow-upInternational Journal of Cardiology, 2013
- Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Direct Intramyocardial Mesenchymal Stromal Cell Injections in Patients with Severe Refractory Angina: One-Year Follow-UpCell Transplantation, 2013
- Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSCCell Communication and Signaling, 2011
- Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory anginaScandinavian Cardiovascular Journal, 2011